Overview
- A UC San Diego analysis of more than 2,500 women in the Women’s Health Initiative found that higher baseline plasma p‑tau217 was linked to substantially increased dementia risk detectable up to 25 years before symptoms.
- The predictive association was strongest in women over 70, those carrying genetic risk for Alzheimer’s, and participants on estrogen plus progestin therapy, according to the study authors.
- In separate Nature Medicine research, a p‑tau217 “clock” estimated the age at which levels become abnormal, and that estimate correlated with age at symptom onset with an error margin of roughly 3–4 years.
- Scripps Research reported a three‑protein structural panel—C1QA, clusterin, and apolipoprotein B—that classified cognitively normal, MCI, and Alzheimer’s cases with about 83% overall accuracy and over 93% in some two‑way comparisons.
- Authors and outside experts say these blood markers are valuable for staging and trial selection but not ready for standalone clinical decisions without larger validation and confirmatory CSF or imaging tests, even as FDA‑cleared blood tests already include p‑tau217.